Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00806468

Acronym

DEPOPA

Enrollment

Registered

2008-12-10

Start date

2009-02-28

Completion date

2011-02-28

Last updated

2010-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

nycturia, Parkinson syndrome, desmopressin, Nocturnal polyuria in patients with Parkinson syndrome

Brief summary

This study will be conducted to study the effect of Desmopressin on the nocturnal micturition frequency in patients with idiopathic Parkinson syndrome.

Interventions

DRUGDesmotabs

Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Male patients with idiopathic Parkinson Syndrome * 18 to 85 years * Nocturnal Pollakisuria \> 2 mictions /night (documented in Screening phase ) * Na+ i.S \> 135 mmol/l * Patient is able to understand all aspects and individual consequences of the clinical trial * An informed consent signed and dated by the patient is available prior to any study specific treatment * The study is consistent with the patients´ request for an appropriate treatment

Exclusion criteria

* Intake of the following concomitant medication: Carbamazepin, Oxcarbazepine, diuretics (Furosemide, Torasemide), non steroidal antiphlogistics, Loperamide, antidiuretic hormone analoga (besides study medication), drugs for treatment of bladder disfunction, in particular anticholinergics * Central Diabetes insipidus * Known heart insufficiency (NYHA Stad. III und IV) * clinical relevant kidney insufficiency * Habitual and psychogenic Polydipsia * Hypersensitivity or allergy against the trial medication or any other ingredient of the trial medication * Participation in another clinical trial during or within 6 months prior to this clinical trial * Medical or psychological condition, which might endanger the proper conduction of the clinical trial * Known drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
average nocturnal micturition frequency within the 2 weeks treatment phase each	6 weeks

Secondary

Measure	Time frame
safety and efficacy on nocturnal micturition frequency of Desmopressin in patients with Parkinson syndrome	8 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026